Compare EEX & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEX | EVMN |
|---|---|---|
| Founded | 2013 | 2020 |
| Country | United States | United States |
| Employees | 821 | 48 |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 890.6M | 869.1M |
| IPO Year | N/A | N/A |
| Metric | EEX | EVMN |
|---|---|---|
| Price | $5.02 | $12.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $7.70 | ★ $43.88 |
| AVG Volume (30 Days) | 76.9K | ★ 1.3M |
| Earning Date | 05-12-2026 | 06-11-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.49 | N/A |
| Revenue Next Year | $6.81 | N/A |
| P/E Ratio | $236.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.32 | $12.51 |
| 52 Week High | $5.45 | $33.20 |
| Indicator | EEX | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 27.91 |
| Support Level | $5.01 | N/A |
| Resistance Level | $5.08 | $24.34 |
| Average True Range (ATR) | 0.02 | 1.70 |
| MACD | -0.01 | -1.05 |
| Stochastic Oscillator | 70.00 | 0.29 |
Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States, with operations in the United Kingdom (U.K.), France, and other markets. The company is engaged in three complementary business lines: Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division provides B2B e-commerce and digital merchandising solutions to manufacturers and retailers. Emerald's key revenue is derived from the Connections business, its only reportable segment.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.